The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Chiasma's Revenue for the
three
months ended in Mar. 2021 was $1.92 Mil. Chiasma's average Accounts Receivable for the
three
months ended in Mar. 2021 was $0.78 Mil.
Hence, Chiasma's Receivables Turnover for the
three
months ended in Mar. 2021 was 2.48.
Chiasma Receivables Turnover Historical Data
The historical data trend for Chiasma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chiasma's Receivables Turnover
For the Biotechnology subindustry, Chiasma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiasma's Receivables Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiasma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Chiasma's Receivables Turnover falls into.
Chiasma Receivables Turnover Calculation
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Chiasma's Receivables Turnover for the fiscal year that ended in Dec. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Chiasma Receivables Turnover Related Terms
Thank you for viewing the detailed overview of Chiasma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHMA has been successfully added to your 